Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000902219-24-000469
Filing Date
2024-11-08
Accepted
2024-11-08 10:52:39
Documents
2

Document Format Files

Seq Description Document Type Size
1 SEC SCHEDULE 13G SEC13G_Filing.htm SC 13G/A 29820
2 JOINT FILING AGREEMENT Rule13D_JointFilingAgreement.htm EX-99 4404
  Complete submission text file 0000902219-24-000469.txt   36157
Mailing Address C/O WELLINGTON MANAGEMENT COMPANY LLP 280 CONGRESS STREET BOSTON MA 02210
Business Address C/O WELLINGTON MANAGEMENT COMPANY LLP 280 CONGRESS STREET BOSTON MA 02210 6179515000
WELLINGTON MANAGEMENT GROUP LLP (Filed by) CIK: 0000902219 (see all company filings)

EIN.: 042683227 | State of Incorp.: MA | Fiscal Year End: 1231
Type: SC 13G/A
SIC: 0000

Mailing Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Business Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 (650) 866-8548
Denali Therapeutics Inc. (Subject) CIK: 0001714899 (see all company filings)

EIN.: 463872213 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A | Act: 34 | File No.: 005-90223 | Film No.: 241438667
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)